ClinicalTrials.gg
CompletedNCT00745550Updated Apr 20, 2012

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

A Phase 1/2 interventional study of SB1518 in Myelofibrosis, Myeloproliferative Disorders and Polycythemia Vera, sponsored by S*BIO. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-20.

Sponsored by S*BIO · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Enrollment
7th of 18
55 · median 35
Started
2008
with 1 other
Phase 1/2
2 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
2 of 18
S*BIO

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 2 in phase 1/2, and was the 2nd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis (CIMF) regardless of their JAK2 mutational status. The second portion of the study is a Phase 2 study to define the efficacy and safety profile of single agent SB1518 at the recommended dose in subjects with CIMF.

03

Conditions studied

  • Myelofibrosis
  • Myeloproliferative Disorders
  • Polycythemia Vera
  • Essential Thrombocythemia

Keywords

  • SB1518
  • Chronic Idiopathic Myelofibrosis
  • Myeloproliferative disorders
  • Polycythemia Vera
  • Essential Thrombocythemia
  • JAK2 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with CIMF (including post ET/PV MF) requiring therapy, including:
  • (ECOG) performance status 0-2
  • Men of who can agree to practice effective during the entire study period and for one month after the last study treatment
  • Women of who have a negative pregnancy test within 14 days prior to the first dose of study drug and can agree to practice effective contraception during the entire study period and for one month after the last study treatment, unless documentation of infertility exists
  • Subjects who are able to understand and willing to sign the form

Exclusion criteria

Exclusion Criteria

  • Subjects with uncontrolled inter-current illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as judged by treating physician. Subjects receiving antibiotics for infections that are under control may be included in the study unless the antibiotic is a inducer/inhibitor
  • Subjects known to be -positive
  • Subjects with known active hepatitis A, B, or C, or latent
  • Women who are pregnant or lactating
  • Subjects with prior radiation therapy to more than 20% of the hematopoietic marrow (prior radiation to spleen is allowed)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Interventions

  • DrugSB1518

    SB1518 taken orally daily for 28 consecutive days in a 28-day cycle

06

What researchers measure

Primary outcomes

  1. Phase 1: to establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily

    Time frame: Throughout the study

  2. Phase 2: to assess the clinical benefit rate in subjects with CIMF who are treated with SB1518 at the recommended dose

    Time frame: Throughout the study

Secondary outcomes

  1. Assess the safety and tolerability of SB1518, administered orally once daily in subjects with CIMF

    Time frame: Throughout the study

  2. Assess the pharmacokinetic profile of SB1518

    Time frame: Throughout the study

  3. Assess the pharmacodynamic profile of SB1518

    Time frame: Throughout the study

07

Study locations

6 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3002, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
08

References and documents

Publications

  • Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T, Campbell MS, Mesa RA. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649-55. doi: 10.1182/blood-2013-02-484832. Epub 2015 Mar 11. PubMed 25762180 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2008
First posted
Sep 3, 2008
Start
Aug 2008
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Apr 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00745550
Lead sponsor
S*BIO
Responsible party
Sponsor
First posted
Sep 3, 2008
Start date
Aug 2008
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Apr 20, 2012

Study contacts

John Seymour, M.D.
principal investigator · Peter MacCallum Cancer Centre, Australia
Andrew Roberts, M.D.
principal investigator · Melbourne Health
Bik To, MD
principal investigator · Royal Adelaide Hospital
Rami Komrokji, MD
principal investigator · H. Lee Moffitt Cancer Center and Research Institute
Martha Wadleigh, MD
principal investigator · Dana-Farber Cancer Institute
Ruben Mesa, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion